For the quarter ending 2025-09-30, CDTX made $94,023,000 in revenue. -$83,340,000 in net income. Net profit margin of -88.64%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| General and administrative | - | - | - | 5,153,750 |
| Total revenues | 0 | 0 | - | 324,333.333 |
| Acquired in-process research and development | 45,000,000 | 0 | - | 0 |
| Research and development | 35,529,000 | 24,817,000 | 24,600,000 | 26,396,500 |
| General and administrative | 8,099,000 | 6,502,000 | 6,179,000 | - |
| Reversal due to settlement of indirect tax liabilities | 0 | -3,935,000 | -5,510,000 | - |
| Total operating expenses | 88,628,000 | 27,384,000 | 25,269,000 | 31,848,500 |
| Loss from operations | -88,628,000 | -27,384,000 | -25,269,000 | -31,362,000 |
| Other expense, net | 0 | 0 | 110,000 | - |
| Interest income, net | 5,395,000 | 1,666,000 | 1,899,000 | 1,089,000 |
| Total other income, net | 5,395,000 | 1,666,000 | 1,789,000 | 1,089,000 |
| Net loss from continuing operations before income tax expense | - | - | - | -30,273,000 |
| Net loss from continuing operations | -83,233,000 | -25,718,000 | -23,480,000 | -30,273,000 |
| (loss) income from discontinued operations (including loss on disposal of discontinued operations of zero and 1,799 during the three and nine months ended september 30, 2024, respectively), net of income taxes | 0 | 0 | - | -1,043,500 |
| Net loss | -83,233,000 | -25,718,000 | -23,480,000 | -31,316,500 |
| Unrealized loss on available-for-sale investments | -107,000 | - | - | - |
| Comprehensive loss | -83,340,000 | - | - | - |
| Basic net loss per common share (in dollars per share) | -3.1 | -1.65 | -1.66 | -2.155 |
| Diluted net loss per common share (in dollars per share) | -3.1 | -1.65 | -1.66 | -2.155 |
| Shares used to compute basic net earnings (loss) per common share (in shares) | 26,882,366 | 15,547,403 | 14,177,743 | -2,372,126 |
| Shares used to compute diluted net earnings (loss) per common share (in shares) | 26,882,366 | 15,547,403 | 14,177,743 | -2,372,126 |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)